KineMed, Inc. Reports Clinical Data on Novel Method for Identifying and Verifying Biomarker Candidates in Cerebral Spinal Fluid for Parkinson's Disease to The Michael J. Fox Foundation
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.